Louati Rim, Abdelmoula N Bouayed, Trabelsi Imen, Abid Dorra, Lissewski Christina, Kharrat Najla, Kamoun Samir, Zenker Martin, Rebai Tarek
Department of Histology, Medical University of Sfax, Center of Biotechnology of Sfax, Sfax, Tunisia.
Cardiology Service, Hedi Chaker Hospital, Center of Biotechnology of Sfax, Sfax, Tunisia.
Mol Syndromol. 2014 Aug;5(5):212-7. doi: 10.1159/000362898. Epub 2014 May 23.
Noonan syndrome (NS) and related disorders, which are now summarized under the term RASopathies, are caused by germline mutations in genes encoding protein components of the Ras/mitogen-activated protein kinase pathway. In this study, we evaluated the clinical and molecular spectrum of 21 Tunisian patients, recruited by a cardiology unit, for whom RASopathy diagnosis was suspected by clinical geneticists. Overall, 19 patients had a clinical diagnosis of NS and 2 were classified as having Cardiofaciocutaneous (CFC) syndrome. In 52% (n = 11) of patients, a RASopathy has been molecularly confirmed. Mutations in PTPN11 and SOS1 genes were found in patients with diagnosis of NS and BRAF gene mutations in patients with CFC syndrome. As reported from other cohorts, mutations in exons 3 and 8 of the PTPN11 gene predominated in Tunisian NS patients. A very uncommon PTPN11 mutation c.5C>T (p.T2I), the functional consequences of which have so far remained unclear, was identified in one patient. As biased by the mode of recruitment, all patients included in this study had a congenital heart defect, with pulmonary valve stenosis being the most frequent one. Short stature and developmental abnormalities were present in mutation-positive cases. This is the first molecular study in patients from southern Tunisia with RASopathy diagnosis.
努南综合征(NS)及相关疾病,现被归纳在“RAS病”这一术语之下,是由编码Ras/丝裂原活化蛋白激酶途径蛋白质成分的基因种系突变引起的。在本研究中,我们评估了21名突尼斯患者的临床和分子谱,这些患者由一个心脏病科招募,临床遗传学家怀疑他们患有RAS病。总体而言,19名患者临床诊断为NS,2名被归类为患有心脏颜面皮肤综合征(CFC)。在52%(n = 11)的患者中,RAS病得到了分子学确认。在诊断为NS的患者中发现了PTPN11和SOS1基因的突变,在CFC综合征患者中发现了BRAF基因突变。正如其他队列所报道的,PTPN11基因第3和8外显子的突变在突尼斯NS患者中占主导。在一名患者中鉴定出一种非常罕见的PTPN11突变c.5C>T(p.T2I),其功能后果迄今仍不清楚。受招募方式的影响,本研究纳入的所有患者都有先天性心脏缺陷,其中肺动脉瓣狭窄最为常见。身材矮小和发育异常出现在突变阳性病例中。这是突尼斯南部诊断为RAS病患者的第一项分子研究。